Healthcare Industry News: Wright Medical Group
News Release - May 31, 2007
Brian Ennis Appointed President and Chief Executive Officer of ETEX Corporation
CAMBRIDGE, Mass., May 31 (HSMN NewsFeed) -- ETEX Corporation today announced that Brian T. Ennis has been appointed as the Company's new President and Chief Executive Officer, effective May 29, 2007.Mr. Ennis has more than 25 years of medical device sales, marketing and executive management experience in both domestic and international markets. Prior to joining ETEX, Mr. Ennis served as President of Empi, Inc., a subsidiary of Encore Medical Corporation; before that he served as President of International at Wright Medical Group. Mr. Ennis also served at Stryker Corporation for 11 years in a variety of domestic and international marketing and general management roles.
"We are extremely excited to have Brian join our talented team. Brian has the experience, track record and skills to lead the company's biomaterials technology expansion and commercialization efforts in the market-driving areas of skeletal repair and regeneration," commented ChinKyu Huh, ETEX's Chairman of the Board.
Brian Ennis commented "It is a privilege to join the ETEX family. ETEX has tremendous upside due to their established and potential strategic partnerships and their proven technology. Products in development have great potential to improve clinical outcomes in a broad range of applications including spine, general orthopedics, neurosurgery, interventional radiology, and sports medicine."
ETEX Corporation develops, manufactures and commercializes proprietary calcium phosphate based biomaterials for skeletal repair and regeneration. The Company is focused on expanding applications for its proprietary bioresorbable materials technology through combination with cells, biologics, or therapeutic agents delivered in minimally invasive, easy to use systems.
For more information, please visit http://www.etexcorp.com .
Source: ETEX Corporation
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
